Journal
PROTEIN AND PEPTIDE LETTERS
Volume 26, Issue 7, Pages 479-493Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/0929866526666190311163820
Keywords
Bispecific antibodies; monoclonal antibodies; combination therapy; monotherapy; cancers/tumors; therapeutic agent
Categories
Ask authors/readers for more resources
Development of cancers mostly involves more than one signal pathways, because of the complicated nature of cancer cells. As such, the most effective treatment option is the one that stops the cancer cells in their tracks by targeting these signal pathways simultaneously. This explains why therapeutic monoclonal antibodies targeted at cancers exert utmost activity when two or more are used as combination therapy. This notwithstanding, studies elsewhere have proven that when bispecific antibody (bsAb) is engineered from two conventional monoclonal antibodies or their chains, it produces better activity than when used as combination therapy. This therefore presents bispecific antibody (bsAb) as the appropriate and best therapeutic agent for the treatment of such cancers. This review therefore discusses the various engineering formats for bispecific antibodies (bsAbs) and their applications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available